Join our daily newsletter At The Bell to receive exclusive market insights
ResMed (ASX:RMD) has reported it received an exemption from the current U.S. Administration, meaning it can keep sending its products from Australia and Singapore to the U.S. tariff-free.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Supposedly having been confirmed on April 5, that bombshell hit the market today via ResMed’s latest quarterly webcast, also released on Thursday.
(Worth reminding: ResMed is also listed on the NYSE.)
So how does ResMed get an exemption while nobody else can? That’s because of something called the Nairobi Protocol – an international agreement that means products treating persons with a disability are not subject to trade barriers.
That could be a liberal application of the protocol: ResMed sells products for sleep disorders.
At any rate, that’s not the only big thing to raise an eyebrow over. Probably the bigger point is: Is the U.S. Government’s word worth anything at all?
More market news
Kowtow: “Biggest day in financial history” on Trump’s tariffs retreat
Meet GeoGeorge: The HotCopper poster so accurate he got hired as an analyst
That was a point ResMed’s management noted in its webcast, to be fair. Mick Farrell ultimately said – though, in nicer words than mine – ‘nothing [is] certain.’
No kidding.
RMD last traded at $36.14/sh.
Join the discussion: See what HotCopper users are saying about Resmed and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
